These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12874768)

  • 21. Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features.
    Grogan TM
    Semin Diagn Pathol; 2003 Aug; 20(3):211-25. PubMed ID: 14552432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice.
    Gole L; Lin A; Chua C; Chng WJ
    Cancer Genet; 2014; 207(1-2):31-4. PubMed ID: 24485403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmablastic multiple myeloma with Dutcher bodies.
    Jain D; Singh T
    Indian J Pathol Microbiol; 2008; 51(3):442-3. PubMed ID: 18723987
    [No Abstract]   [Full Text] [Related]  

  • 24. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular and extracellular rhomboid shaped crystalline inclusions in a case of IgG lambda restricted plasma cell myeloma: a case report and review of the literature.
    Matoso A; Rizack T; Treaba DO
    Diagn Pathol; 2010 Jan; 5():6. PubMed ID: 20205792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients.
    Ng MH; Kan A; Chung YF; Wong IH; Lo KW; Wickham NW; Lei KI; Lee JC
    Am J Pathol; 1999 Jan; 154(1):15-22. PubMed ID: 9916913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of plasma cell morphology in multiple myeloma.
    Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
    Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified Culture System and Combination of FICTION Could Increase the Detection Rate of Abnormalities in Multiple Myeloma.
    Fu Q; Xie S; Chen J; Huang H
    Ann Clin Lab Sci; 2021 Jan; 51(1):61-72. PubMed ID: 33653782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma cell myeloma with unusual morphology--a series of 6 cases.
    Gupta R; Hussain N; Rahman K; Nityanand S
    Eur J Haematol; 2014 Aug; 93(2):165-70. PubMed ID: 24628605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary plasma cell leukaemia (PCL) with plasmablastic morphology.
    Xu K; Nacheva E
    J Hematop; 2024 Jun; 17(2):117-119. PubMed ID: 38580782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
    Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
    Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining IgM multiple myeloma.
    Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
    Am J Hematol; 2011 Aug; 86(8):717; author reply 718-9. PubMed ID: 21761439
    [No Abstract]   [Full Text] [Related]  

  • 35. [The immunological phenotype and proliferative activity of the tumor lymphocytes in multiple myeloma].
    Golenkov AK; Nazarova IN; Sarycheva TG; Miterev GIu; Kozinets GI
    Ter Arkh; 1993; 65(7):38-41. PubMed ID: 8211777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytogenetic analysis and fluorescence in situ hybridization in a case of IgD multiple myeloma.
    Weinländer G; Drach J; Raderer M; Okamoto I; Ackermann J; Stögermayer B; Fazeny B; Nowotny H; Marosi C
    Cancer Genet Cytogenet; 1998 Sep; 105(2):172-6. PubMed ID: 9723037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease.
    Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M
    J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined cytogenetic testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma.
    Wiktor A; Van Dyke DL
    Cancer Genet Cytogenet; 2004 Aug; 153(1):73-6. PubMed ID: 15325099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple myeloma and acute megakaryoblast leukemia in spent phase polycythemia vera.
    Terpstra WE; Meuwissen OJ; Hagemeijer A; Michiels JJ
    Am J Clin Pathol; 1990 Dec; 94(6):786-90. PubMed ID: 2244596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multiple myeloma immunophenotyping: method validation].
    Vergnolle I; Rieu JB; Avet-Loiseau H; Corre J; Vergez F
    Ann Biol Clin (Paris); 2019 Apr; 77(2):197-217. PubMed ID: 30998199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.